JPMorgan Chase & Co. Acquires 64,920 Shares of Merit Medical Systems, Inc. $MMSI

JPMorgan Chase & Co. increased its holdings in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 7.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 917,122 shares of the medical instruments supplier’s stock after purchasing an additional 64,920 shares during the quarter. JPMorgan Chase & Co. owned 1.55% of Merit Medical Systems worth $76,332,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. State Street Corp lifted its stake in Merit Medical Systems by 1.1% during the 2nd quarter. State Street Corp now owns 2,218,432 shares of the medical instruments supplier’s stock valued at $207,379,000 after acquiring an additional 24,569 shares during the period. Geode Capital Management LLC raised its holdings in shares of Merit Medical Systems by 2.8% during the second quarter. Geode Capital Management LLC now owns 1,437,397 shares of the medical instruments supplier’s stock valued at $134,384,000 after purchasing an additional 39,620 shares during the last quarter. Maverick Capital Ltd. lifted its position in Merit Medical Systems by 8.4% during the second quarter. Maverick Capital Ltd. now owns 1,379,408 shares of the medical instruments supplier’s stock valued at $128,947,000 after purchasing an additional 106,897 shares during the period. Franklin Resources Inc. boosted its holdings in Merit Medical Systems by 25.9% in the second quarter. Franklin Resources Inc. now owns 884,607 shares of the medical instruments supplier’s stock worth $82,693,000 after purchasing an additional 181,815 shares during the last quarter. Finally, Westwood Holdings Group Inc. grew its position in Merit Medical Systems by 11.9% in the 2nd quarter. Westwood Holdings Group Inc. now owns 768,970 shares of the medical instruments supplier’s stock worth $71,883,000 after purchasing an additional 81,469 shares during the period. 99.66% of the stock is currently owned by institutional investors.

Key Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q4 beat — Merit reported $1.04 EPS versus the $0.96 consensus and revenue of $393.94M vs. $390.77M, with revenue up ~10.9% year-over-year; these results directly support the share-price uptick. Read More.
• Positive Sentiment: Raised FY2026 guidance — Management set FY26 EPS guidance of $4.010–4.150 versus the street at ~3.73, which boosts forward earnings expectations and valuation support. Read More.
• Neutral Sentiment: Key operating metrics — Return on equity (~14.3%) and net margin (~8.0%) were disclosed; these confirm healthy profitability but also imply a premium multiple (P/E ~42), so upside depends on durable margin expansion. Read More.
• Neutral Sentiment: Investor materials & call available — Management hosted a conference call and posted slides/transcript (useful for hearing color on procedure demand, margins, and buyback/capex plans). Read More.
• Neutral Sentiment: Media coverage — Multiple outlets summarized the beat and guidance; these stories help circulate the positive surprise but add no new company-specific data. Read More.

Merit Medical Systems Stock Up 1.0%

MMSI stock opened at $82.43 on Wednesday. Merit Medical Systems, Inc. has a twelve month low of $77.62 and a twelve month high of $107.27. The company has a quick ratio of 2.86, a current ratio of 4.28 and a debt-to-equity ratio of 0.48. The stock has a market cap of $4.89 billion, a P/E ratio of 42.27, a PEG ratio of 2.22 and a beta of 0.61. The business’s 50-day moving average price is $84.08 and its 200-day moving average price is $84.98.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on MMSI shares. Piper Sandler lowered their price target on Merit Medical Systems from $113.00 to $106.00 and set an “overweight” rating on the stock in a report on Wednesday, February 18th. Robert W. Baird set a $108.00 target price on Merit Medical Systems in a report on Tuesday, December 16th. Zacks Research downgraded Merit Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. BTIG Research initiated coverage on shares of Merit Medical Systems in a research report on Friday, February 6th. They set a “buy” rating and a $107.00 price target for the company. Finally, Canaccord Genuity Group raised their price objective on shares of Merit Medical Systems from $93.00 to $99.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.67.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.